AZD3355 Dose-escalation study in healthy males
Study identifier:D9120C00030
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase 1 single centre single-blind randomised placebo-controlled study to assess the safety, tolerability and pharmacokinetics of oral AZD3355 after administration of single ascending doses and multiple repeated doses in healthy male volunteers
Medical condition
Reflux disease
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD3355, Placebo
Sex
Male
Actual Enrollment
54
Study type
Interventional
Age
18 Years - 45 Years
Date
Study Start Date: 01 Sept 2008
Primary Completion Date: 01 Dec 2008
Study Completion Date: 01 Dec 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD3355 capsules, oral, single or twice daily dose Other Name: Lesogaberan |
| Placebo Comparator: 2 | Drug: Placebo To match dosing of AZD3355 |
Contacts
Investigators
Principal Investigator
Marianne Hartford
CPU Avd 102, Gröna Stråket 12, Sahlgrenska Universitetssjukhuset, 413 45 Göteborg
